China Biologic Grants Exclusive Overseas Rights of TQC3721 to AstraZeneca for Up to $1.9B

According to China Biologic's official announcement, the company has granted exclusive overseas rights of TQC3721, a novel COPD (chronic obstructive pulmonary disease) therapy and PDE3/4 inhibitor, to AstraZeneca for a total consideration of up to $1.9 billion. The deal represents a significant biotech licensing agreement for the company in 2026.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments